Recursion Pharmaceuticals Inc (RXRX)

NASDAQ
Currency in USD
7.53
+0.04(+0.53%)
Closed
After Hours
7.51-0.02(-0.27%)
RXRX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
7.147.72
52 wk Range
5.6015.74
Key Statistics
Edit
Prev. Close
7.49
Open
7.24
Day's Range
7.14-7.72
52 wk Range
5.6-15.74
Volume
16.28M
Average Volume (3m)
13.15M
1-Year Change
-29.61%
Book Value / Share
1.87
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RXRX Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
9.14
Upside
+21.42%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week
Show more

Recursion Pharmaceuticals Inc Company Profile

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Compare RXRX to Peers and Sector

Metrics to compare
RXRX
Peers
Sector
Relationship
P/E Ratio
−7.9x−1.6x−0.6x
PEG Ratio
1.82−0.040.00
Price/Book
5.7x1.5x2.6x
Price / LTM Sales
45.6x16.2x3.1x
Upside (Analyst Target)
33.0%197.8%51.5%
Fair Value Upside
Unlock14.1%7.6%Unlock

Analyst Ratings

2 Buy
6 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 9.14
(+21.42% Upside)

Earnings

Latest Release
Nov 07, 2024
EPS / Forecast
-0.34 / -0.33
Revenue / Forecast
26.10M / 12.62M
EPS Revisions
Last 90 days

People Also Watch

38.64
NBIS
-2.23%
2.410
QSI
+1.26%
8.75
NNOX
-2.78%
26.29
BEAM
-0.38%
33.500
SYM
+0.63%

FAQ

What Is the Recursion Pharmaceuticals (RXRX) Stock Price Today?

The Recursion Pharmaceuticals stock price today is 7.53

What Stock Exchange Does Recursion Pharmaceuticals Trade On?

Recursion Pharmaceuticals is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Recursion Pharmaceuticals?

The stock symbol for Recursion Pharmaceuticals is "RXRX."

What Is the Recursion Pharmaceuticals Market Cap?

As of today, Recursion Pharmaceuticals market cap is 2.99B.

What is Recursion Pharmaceuticals Earnings Per Share?

The Recursion Pharmaceuticals EPS is -1.54.

What Is the Next Recursion Pharmaceuticals Earnings Date?

Recursion Pharmaceuticals will release its next earnings report on 03 Mar 2025.

From a Technical Analysis Perspective, Is RXRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.